BWXT and GMS Form Joint Venture in Nuclear Medicine Manufacturing and Distribution in the Asia-Pacific Region
(LYNCHBURG, Va. – March 8, 2021) – BWXT Medical Ltd. (BWXT Medical) and Global Medical Solutions, Ltd. (GMS) have entered into a joint venture (JV) to manufacture and distribute radioisotopes and radiopharmaceuticals in the Asia-Pacific (Asia).
BWXT Names Nuclear Medicine Business as BWXT Medical
(LYNCHBURG, Va. – Feb. 1, 2021) – BWX Technologies, Inc. (NYSE: BWXT) today announced that its subsidiary BWXT ITG Canada, Inc., a nuclear medicine company, has been renamed BWXT Medical Ltd. (BWXT Medical), in order to better align with the company’s products, customer base and strategy.
OPG and BWXT Make Significant Progress in Production of Life-Saving Medical Isotope at Darlington Nuclear Generating Station
Darlington to become first large-scale nuclear station to produce molybdenum-99.
BWXT Appoints Martyn Coombs to lead Nuclear Medicine Business as President, BWXT ITG Canada
(LYNCHBURG, Va. – July 6, 2020) – BWX Technologies, Inc. (NYSE: BWXT) today announced that Martyn Coombs has been appointed president, BWXT ITG Canada, Inc. (BWXT ITG Canada), effective July 20, 2020. In this role, Coombs will have P&L responsibility for BWXT’s medical isotope business, based in Canada, with facilities in Kanata, Ontario and Vancouver, British Columbia. In addition to leading the existing business, Coombs will also be responsible for guiding the successful launch of BWXT’s technetium-99m generator product line currently in development, and growing the overall business. Coombs will be replacing Tom Burnett, who is retiring.
BWXT Successfully Demonstrates Labeling of Cold Kits with its Mo-99 / Tc-99m Technology
BWXT announced today that it has successfully labeled technetium-99m (Tc-99m) derived from its proprietary molybdenum-99 (Mo-99) production process and its proprietary Tc-99m generators with nine of the most widely used cold kits in the North American market.
BWXT Announces Availability of FDA-Approved Indium In-111 Oxyquinoline Solution
(LYNCHBURG, Va. – September 26, 2019) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT ITG Canada, Inc., having received approval from the U.S. Food and Drug Administration (FDA) on its abbreviated new drug application for its generic version of Indium In-111 Oxyquinoline Solution, is now making the product available for sale in the United States.